Other Clinical Trial - Study to Assess Adverse Events & How Intravenous

Status Completed

Clinical Trial Summary

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV infection is considered to be a chronic disease requiring lifelong therapy. This study will evaluate how safe ABBV-382 is and how it is absorbed, distributed and eliminated from the body in adult participants with HIV-1 infection. ABBV-382 is an investigational drug being developed for the treatment of HIV-1 infection. This study takes place in 2 parts. In Part A, participants with HIV-1 and no history of combination antiretroviral therapy (cART) or who are off cART for more than 3 months will be enrolled to receive ABBV-382. In Part B, participants with no virus in their blood and on maintenance cART will be enrolled into one of the intravenous (IV) or subcutaneous (SC) groups. In the IV groups, participants will receive either placebo or ABBV-382 whereas participants in the SC group will receive ABBV-382. There is 1 in 3 chance that participants will receive placebo (no drug) in Part B IV groups. The IV group in Part B is double-blinded which means neither the study doctors nor the participants will know who will be given study drug or placebo. Around 52 adult participants with HIV-1 infection will be enrolled at approximately 21 sites across the United States, including Puerto Rico. Participants in Part A will receive an intravenous (IV) dose of ABBV-382 on Day 1. Participants in Part B will receive an IV or SC dose of ABBV-382 or placebo on Days 1, 29 and 57. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and presence of side effects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acquired Immunodeficiency Syndrome
HIV Infections
Human Immunodeficiency Virus (HIV)
Immunologic Deficiency Syndromes

Clinical Trial Details

NCT number	NCT04554966
Study type	Interventional
Source	AbbVie
Contact
Status	Completed
Phase	Phase 1
Start date	April 16, 2021
Completion date	August 14, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02511496` - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia	N/A
Completed	`NCT02234492` - The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients	Phase 4
Completed	`NCT02027441` - Enhanced Prevention in Couples: Feasibility Study #2	N/A
Completed	`NCT01685372` - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults	Phase 2
Completed	`NCT02165202` - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis	Phase 2
Completed	`NCT01615601` - An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients	Phase 4
Terminated	`NCT01448486` - A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV	Phase 4
Completed	`NCT01449006` - A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)	Phase 4
Completed	`NCT02572401` - Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men	N/A
Completed	`NCT04122404` - POC Strategies to Improve TB Care in Advanced HIV Disease	N/A
Completed	`NCT03290755` - Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux
Completed	`NCT02974998` - Cape Town Young Women's Health CoOp	N/A
Completed	`NCT01516970` - Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)	Phase 3
Completed	`NCT01997346` - Multi-level Determinants of Starting ART Late: Aim 2	N/A
Active, not recruiting	`NCT01875952` - Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)	Phase 4
Completed	`NCT01199939` - A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients	Phase 2
Completed	`NCT03783130` - Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults	Phase 1
Recruiting	`NCT05657106` - Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk	N/A
Not yet recruiting	`NCT05727033` - Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections	N/A
Completed	`NCT01053741` - Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms